Article citationsMore>>
Zhong, W.-Z., Wang, Q., Mao, W.-M., et al. (2018) Gefitinib versus Vinorelbine plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC (ADJUVANT/CTONG1104): A Randomised, Open-Label, Phase 3 Study. The Lancet Oncology, 19, 139-148.
https://doi.org/10.1016/S1470-2045(17)30729-5
has been cited by the following article:
Related Articles:
-
Adnan Aydiner
-
Anatoly Boleslavovich Smulevich, Natalia Alekseevna Ilyina, Victoria Valentinovna Chitlova
-
Ashish C. Suthar, Vikas G. Pai, Yogesh Kadam, Aniruddha Tongaonkar, Shailaja Kale, Atul B. Deshpande, Sharat Kolke, Snehal Tanna, Shrikant V. Deshpande, Purvi Chawla, Debjit Biswas, Somesh Sharma
-
Hideki Bou, Akira Tokunaga, Hideyuki Suzuki, Nobuo Murata, Yasuyuki Sugiyama, Naoto Fukuda, Masahiro Ishimaru, Hiroyuki Suzuki
-
Jacqueline C. Dominguez, Arlene R. Ng, Ludwig F. Damian